The Food and Drug Administration on Friday authorized Florida to establish the nation’s first state program for importing certain lower-cost prescription drugs from Canada, a long-debated policy shift that could test whether international price differences can be used to reduce U.S. drug spending without weakening supply-chain safeguards.

The FDA authorization applies to Florida’s Section 804 Importation Program, or SIP. The agency stressed that the decision is only the first step: Florida cannot simply begin buying Canadian medicines immediately. Before shipments arrive, the state must submit drug-specific information, demonstrate authenticity and testing, relabel products to conform with FDA requirements and maintain systems for adverse-event reporting, recalls and supply-chain integrity.

Florida is the first state to receive this form of federal authorization after years of debate over drug importation. The Associated Press reported that other states have pursued similar plans, but none had previously cleared FDA review. The authorization therefore creates the first practical test of a policy discussed by both Republican and Democratic administrations.

A two-year authorization with substantial conditions

FDA said Florida’s authorization will last for two years beginning when the agency is notified of the first shipment. The state must show that imported medicines can produce significant consumer savings without imposing additional public-health risk. Those twin requirements come directly from Section 804 of the Federal Food, Drug, and Cosmetic Act.

The federal framework was implemented through a 2020 final rule. It limits each importation supply chain and requires approved foreign sellers and U.S. importers, unique product identifiers, laboratory testing and records that allow packages to be traced through the system. Certain categories of medicines, including biologics and controlled substances, are excluded.

The FDA’s compliance guidance explains that the rule is intended to permit selected Canadian imports only when the program can achieve significant savings while adding no risk to public health and safety. That standard is higher than simply showing that the Canadian list price is lower.

Florida projects large savings, but execution will determine the result

Florida officials said the program could save up to $180 million in its first year. The governor’s January 5 announcement says the state plans to begin with selected maintenance medicines for chronic conditions including HIV/AIDS, mental illness, prostate cancer and urea-cycle disorders. Initial patients would be served through state agencies, with a later expansion to Medicaid contemplated.

Those savings remain projections rather than demonstrated results. FDA’s own regulatory analysis of the 2020 rule said the agency lacked enough information to estimate how much medicine would ultimately be imported or how large consumer savings would be. The economics depend on drug selection, Canadian supply, contracting, testing, distribution and how much of the price difference survives those operational costs.

Canada’s market is much smaller than the United States, which has fueled concerns about whether large-scale American importation could strain Canadian supplies. Pharmaceutical manufacturers have also opposed broad importation, arguing that U.S. regulators cannot assume foreign distribution channels will provide the same controls as the domestic system.

The policy spans administrations

The current framework emerged through several administrations rather than a single partisan initiative. In September 2020, FDA announced final actions implementing a pathway for state-sponsored Canadian imports. The Biden administration later directed FDA to continue working with states and tribes interested in importation as part of a broader competition strategy for prescription drugs.

Florida submitted its proposal more than three years before Friday’s authorization and later sued FDA over delays. The state portrayed the approval as validation of its argument that carefully controlled importation can lower costs for public programs. FDA, by contrast, framed the action as a regulatory authorization conditioned on continuing compliance rather than an endorsement of Florida’s projected savings.

That distinction is important because the state still must provide detailed information for each drug it proposes to import. Imported products must correspond to FDA-approved medicines, pass authenticity and quality testing, carry compliant U.S. labeling and move through an approved supply chain.

The first program will test a long-running drug-price theory

U.S. prescription drug prices are frequently higher than prices for the same or comparable products in Canada, where public purchasing and price regulation play larger roles. Importation advocates have long argued that allowing American buyers to access those prices could create direct savings and increase competitive pressure on manufacturers.

Opponents counter that the apparent price gap does not automatically translate into a workable cross-border market. Canada has its own supply requirements, manufacturers control where products are distributed, and U.S. law imposes additional testing, labeling and tracking obligations. The policy question is therefore not merely whether Canadian prices are lower, but whether a regulated importation chain can reliably deliver those savings at meaningful scale.

Florida now becomes the first state positioned to answer that question through an authorized program. FDA Commissioner Robert Califf said the agency would work with states and tribes but emphasized that proposals must demonstrate significant cost savings without adding exposure to unsafe or ineffective drugs.

The approval does not guarantee that medicines will begin flowing quickly, nor does it establish that other states will receive identical treatment. What it does establish is a precedent: for the first time, FDA has concluded that a state’s Section 804 proposal can proceed to implementation under federal oversight. The next test is operational—whether Florida can satisfy the remaining drug-by-drug requirements and turn a policy that has been debated for decades into a functioning supply chain that produces measurable savings.